Low
₹3,172.50
High
₹3,221.90
| Previous Close | ₹3,186.40 |
|---|---|
| Day's Range | ₹3,172.50 - ₹3,221.90 |
| Open | ₹3,190.00 |
| 52 Week Range | ₹3,054.00 - ₹6,410.00 |
| Volume | 9,320 |
| Market Cap | ₹0.01 |
| Trade Value ( ₹ in Lacs) | 297.41 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 3.86 |
| Price/Earning (TTM) | 17.74 |
| TTM EPS (₹) | 179.46 |
| P/E Ratio | 34.06 |
| Book Value(₹) | 9.27 |
| PAT Margin (%) | 15.20 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 46.16 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 5359.0 | 20132.0 |
| Expenses | N/A | N/A |
| PBT | 1653.0 | 4314.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1195.0 | 4135.0 |
| Founded | 1956 |
|---|---|
| Managing Director | Deepak Arora |
| NSE Symbol | SANOFI |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,27,933.39 | 1,787.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,75,833.11 | 6,625.45 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,548.89 | 4,427.50 | 3,132.70 - 3,132.70 |
| Apollo Hospitals Enterprise Ltd. | 1,19,392.31 | 8,300.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,154.89 | 1,400.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,09,568.82 | 1,087.05 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,654.01 | 1,277.80 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,704.91 | 2,265.00 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 96,492.75 | 2,337.90 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 95,090.78 | 977.05 | 903.00 - 903.00 |
No Records Found
In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India has informed that it enclosed press release titled 'Sanofi India Limited appoints Mr. Rahul Bhatnagar as the Chairman of its Board of Directors’.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 28th April 2026, to consider and approve the Unaudited Financial Results for the quarter ended 31st March 2026. Further, in reference to intimation dated 24th March 2026 for closure of trading window, the trading window for the purpose of publication of Unaudited Financial Results of the Company for the quarter ended 31st March 2026 shall remain closed from Wednesday, 1st April 2026 till to Thursday, 30th April 2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zim Laboratories has submitted a copy of newspaper advertisements published in respect of 42nd Annual General Meeting of the Company scheduled to be held on Monday, 29th June, 2026 in the Newspapers, The Financial Express (English) all India Edition, Indian Express (English) Nagpur Edition and Loksatta (Marathi).
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Sanofi India Ltd. is ₹3,186.40 as of 2026-06-05.
The market capitalisation of Sanofi India Ltd. is ₹7,332.37 as of 2026-06-05.
The 1-year return of Sanofi India Ltd. is 0.00% as of 2026-06-05.
The P/E ratio of Sanofi India Ltd. is 28.81 as of 2026-06-07.
The 52-week high and low of Sanofi India Ltd. are ₹6,410.00 and ₹3,054.00, respectively, as of 2026-06-05.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.